Suppr超能文献

相似文献

1
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.
Infect Immun. 1994 Feb;62(2):384-9. doi: 10.1128/iai.62.2.384-389.1994.
2
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.
Clin Gastroenterol Hepatol. 2007 Jun;5(6):707-13. doi: 10.1016/j.cgh.2007.02.025.
3
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.
Clin Gastroenterol Hepatol. 2007 Aug;5(8):964-8. doi: 10.1016/j.cgh.2007.04.018. Epub 2007 Jul 6.
4
IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.
6
Serum antibody response to toxins A and B of Clostridium difficile.
J Infect Dis. 1983 Jul;148(1):93-100. doi: 10.1093/infdis/148.1.93.
7
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Toxins (Basel). 2010 May;2(5):998-1018. doi: 10.3390/toxins2050998. Epub 2010 May 7.
8
Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
J Infect Dis. 1992 Dec;166(6):1287-94. doi: 10.1093/infdis/166.6.1287.
9
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.

引用本文的文献

1
A Mouse Model of Mild Infection for the Characterization of Natural Immune Responses.
Microorganisms. 2024 Sep 24;12(10):1933. doi: 10.3390/microorganisms12101933.
2
Immunization Strategies Against Clostridioides difficile.
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.
3
Host Immune Responses to Infection and Potential Novel Therapeutic Approaches.
Trop Med Infect Dis. 2023 Nov 23;8(12):506. doi: 10.3390/tropicalmed8120506.
4
infection: traversing host-pathogen interactions in the gut.
Microbiology (Reading). 2023 Feb;169(2). doi: 10.1099/mic.0.001306.
5
Towards Development of a Non-Toxigenic Oral Spore Vaccine against Toxigenic .
Pharmaceutics. 2022 May 19;14(5):1086. doi: 10.3390/pharmaceutics14051086.
6
High-resolution structure of native toxin A from Clostridioides difficile.
EMBO Rep. 2022 Jan 5;23(1):e53597. doi: 10.15252/embr.202153597. Epub 2021 Nov 24.
8
Immune response against and translation to therapy.
Therap Adv Gastroenterol. 2021 May 7;14:17562848211014817. doi: 10.1177/17562848211014817. eCollection 2021.
9
Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.
Anaerobe. 2021 Feb;67:102299. doi: 10.1016/j.anaerobe.2020.102299. Epub 2020 Nov 21.

本文引用的文献

2
Purification and characterisation of intracellular toxin A of Clostridium difficile.
J Med Microbiol. 1993 Jan;38(1):69-73. doi: 10.1099/00222615-38-1-69.
3
A solid phase, direct competition, radioimmunoassay for quantitation of secretory IgA in human serum.
J Immunol Methods. 1981;40(3):345-58. doi: 10.1016/0022-1759(81)90366-5.
5
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.
Infect Immun. 1982 May;36(2):822-9. doi: 10.1128/iai.36.2.822-829.1982.
6
Biological activities of toxins A and B of Clostridium difficile.
Infect Immun. 1982 Mar;35(3):1147-50. doi: 10.1128/iai.35.3.1147-1150.1982.
7
Purification and characterization of toxins A and B of Clostridium difficile.
Infect Immun. 1982 Mar;35(3):1032-40. doi: 10.1128/iai.35.3.1032-1040.1982.
9
Serum antibody response to toxins A and B of Clostridium difficile.
J Infect Dis. 1983 Jul;148(1):93-100. doi: 10.1093/infdis/148.1.93.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验